Etrolizumab
Etrolizumab
Etrolizumab (pronunciation: et-ro-li-zu-mab) is a monoclonal antibody designed for the treatment of inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn's disease.
Etymology
The name "Etrolizumab" is derived from the International Nonproprietary Names (INN), where "Etro-" is a prefix used for humanized antibodies, "-lizu-" indicates the drug's targeting of the immune system, and "-mab" is a suffix for monoclonal antibodies.
Mechanism of Action
Etrolizumab works by targeting and inhibiting the beta7 integrin, a protein found on the surface of certain white blood cells. By blocking this protein, etrolizumab prevents these cells from migrating to inflamed areas in the gut, thereby reducing inflammation and symptoms of IBD.
Clinical Trials
Etrolizumab has undergone several clinical trials to evaluate its safety and efficacy in treating IBD. However, as of 2021, it has not yet been approved by the Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
Related Terms
- Monoclonal Antibody
- Inflammatory Bowel Disease
- Ulcerative Colitis
- Crohn's Disease
- Beta7 Integrin
- Clinical Trial
- Food and Drug Administration
- European Medicines Agency
External links
- Medical encyclopedia article on Etrolizumab
- Wikipedia's article - Etrolizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski